SG
AMAG

Societe Generale’s AMAG Pharmaceuticals AMAG Stock Holding History

Societe Generale’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$232K Buy
+9,700
New +$222K ﹤0.01% 2054

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Societe Generale's AMAG Position: Q2 2016 in Review

Societe Generale opened a new position in AMAG Pharmaceuticals (AMAG) in Q2 2016: 9,700 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #2054 among its holdings.

165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

  • Societe Generale held 9,700 shares of AMAG Pharmaceuticals worth $232K as of Q2 2016.
  • AMAG Pharmaceuticals was a new Societe Generale position in Q2 2016.
  • AMAG Pharmaceuticals made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2054 holding.
  • 165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.